@article{cannegieter_covid-19_nodate,
	title = {{COVID}-19 associated coagulopathy and thromboembolic disease: {Commentary} on an interim expert guidance},
	volume = {n/a},
	copyright = {This article is protected by copyright. All rights reserved.},
	issn = {2475-0379},
	shorttitle = {{COVID}-19 associated coagulopathy and thromboembolic disease},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/rth2.12350},
	doi = {10.1002/rth2.12350},
	abstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19, that first occurred in late December 2019 in the city of Wuhan in Hubei Province, China. It has since spread globally, resulting in a WHO declared pandemic, with as yet (17/4/20) more than two million confirmed cases and about 150.000 confirmed deaths. As for every new disease, clinicians, hospitals and governments struggle to find optimal clinical and public health measures to contain its spread and burden. For this, information from scientific research is crucial and fortunately we see a rapidly accumulating output of studies.},
	language = {en},
	number = {n/a},
	urldate = {2020-04-26},
	journal = {Research and Practice in Thrombosis and Haemostasis},
	author = {Cannegieter, Suzanne C. and Klok, Frederikus A.},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12350},
	file = {Full Text PDF:C\:\\Users\\mdwan\\Zotero\\storage\\HF9WECE8\\Cannegieter and Klok - COVID-19 associated coagulopathy and thromboemboli.pdf:application/pdf}
}

{"_id":"FjCdMRi6u4F2WCrQj","bibbaseid":"cannegieter-klok-covid19associatedcoagulopathyandthromboembolicdiseasecommentaryonaninterimexpertguidance","authorIDs":[],"author_short":["Cannegieter, S. C.","Klok, F. A."],"bibdata":{"bibtype":"article","type":"article","title":"COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance","volume":"n/a","copyright":"This article is protected by copyright. All rights reserved.","issn":"2475-0379","shorttitle":"COVID-19 associated coagulopathy and thromboembolic disease","url":"https://onlinelibrary.wiley.com/doi/abs/10.1002/rth2.12350","doi":"10.1002/rth2.12350","abstract":"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19, that first occurred in late December 2019 in the city of Wuhan in Hubei Province, China. It has since spread globally, resulting in a WHO declared pandemic, with as yet (17/4/20) more than two million confirmed cases and about 150.000 confirmed deaths. As for every new disease, clinicians, hospitals and governments struggle to find optimal clinical and public health measures to contain its spread and burden. For this, information from scientific research is crucial and fortunately we see a rapidly accumulating output of studies.","language":"en","number":"n/a","urldate":"2020-04-26","journal":"Research and Practice in Thrombosis and Haemostasis","author":[{"propositions":[],"lastnames":["Cannegieter"],"firstnames":["Suzanne","C."],"suffixes":[]},{"propositions":[],"lastnames":["Klok"],"firstnames":["Frederikus","A."],"suffixes":[]}],"note":"_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12350","file":"Full Text PDF:C\\:\\\\Users\\\\mdwan\\\\Zotero\\\\storage\\F̋9WECE8\\\\Cannegieter and Klok - COVID-19 associated coagulopathy and thromboemboli.pdf:application/pdf","bibtex":"@article{cannegieter_covid-19_nodate,\n\ttitle = {{COVID}-19 associated coagulopathy and thromboembolic disease: {Commentary} on an interim expert guidance},\n\tvolume = {n/a},\n\tcopyright = {This article is protected by copyright. All rights reserved.},\n\tissn = {2475-0379},\n\tshorttitle = {{COVID}-19 associated coagulopathy and thromboembolic disease},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1002/rth2.12350},\n\tdoi = {10.1002/rth2.12350},\n\tabstract = {The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) is the causative pathogen of a new infectious disease, COVID-19, that first occurred in late December 2019 in the city of Wuhan in Hubei Province, China. It has since spread globally, resulting in a WHO declared pandemic, with as yet (17/4/20) more than two million confirmed cases and about 150.000 confirmed deaths. As for every new disease, clinicians, hospitals and governments struggle to find optimal clinical and public health measures to contain its spread and burden. For this, information from scientific research is crucial and fortunately we see a rapidly accumulating output of studies.},\n\tlanguage = {en},\n\tnumber = {n/a},\n\turldate = {2020-04-26},\n\tjournal = {Research and Practice in Thrombosis and Haemostasis},\n\tauthor = {Cannegieter, Suzanne C. and Klok, Frederikus A.},\n\tnote = {\\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12350},\n\tfile = {Full Text PDF:C\\:\\\\Users\\\\mdwan\\\\Zotero\\\\storage\\\\HF9WECE8\\\\Cannegieter and Klok - COVID-19 associated coagulopathy and thromboemboli.pdf:application/pdf}\n}\n\n","author_short":["Cannegieter, S. C.","Klok, F. A."],"key":"cannegieter_covid-19_nodate","id":"cannegieter_covid-19_nodate","bibbaseid":"cannegieter-klok-covid19associatedcoagulopathyandthromboembolicdiseasecommentaryonaninterimexpertguidance","role":"author","urls":{"Paper":"https://onlinelibrary.wiley.com/doi/abs/10.1002/rth2.12350"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1KKS9N-ys_CbcDBaEaF9S5iHVNyMtV51D","creationDate":"2020-04-27T18:21:57.315Z","downloads":0,"keywords":[],"search_terms":["covid","associated","coagulopathy","thromboembolic","disease","commentary","interim","expert","guidance","cannegieter","klok"],"title":"COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance","year":null,"dataSources":["4cyoWuoap7Tf7rdfb"]}